Development of in vitro models to demonstrate the ability of PecSys®, an in situ nasal gelling technology, to reduce nasal run-off and drip

Drug Development and Industrial Pharmacy

Volumn 39, Issue 5, 2013, Pages 816-824

  Castile, Jonathan ^a   Cheng, Yu Hui ^a   Simmons, Ben ^a   Perelman, Michael ^a   Smith, Alan ^a   Watts, Peter ^a  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

Anatomical nasal cast; Formulation; Gels; in situ gelling; in vitro models; Inclined plate; Mucosal drug delivery; Nasal drug delivery; No drip; Pectin

Indexed keywords

CALCIUM ION; ELECTROLYTE; GELLING AGENT; NOSE DROPS; NOSE SPRAY; PECTIN;

ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG DOSAGE FORM COMPARISON; GEL; NOSE CAVITY; NOSE MUCUS; THIN LAYER CHROMATOGRAPHY; THROAT;

ADMINISTRATION, INTRANASAL; DRUG DELIVERY SYSTEMS; GELS; HUMANS; MODELS, THEORETICAL; NASAL MUCOSA; PECTINS;

EID: 84875906871     PISSN: 03639045     EISSN: 15205762     Source Type: Journal    
DOI: 10.3109/03639045.2012.707210     Document Type: Article

References (34)

1. Behl CR, Pimplaskar HK, Sileno J, deMeireles J, Romeo VD. (1998). Effects of physicochemical properties and other factors on systemic nasal drug delivery. Adv Drug Delivery Rev, 29:89-116.
2. Watts P, Smith A. (2009). PecSys: In situ gelling system for optimised nasal drug delivery. Expert Opin Drug Deliv, 6:543-552.
3. May, CD. (1990). Industrial pectins: Sources, production and applications. Carbohydrate Polymers, 12:79-99.
4. Rolin C. (1993). Pectin. In: Whistler RL, BeMiller JN, eds. Industrial Gums. New York: Academic Press, 257-293.
5. Grant GT, Morris ER, Rees DA, Smith PJC, Thom D. (1973). Biological interactions between polysaccharides and divalent cations: The egg-box model. FEBS Letters, 32:195-198.
6. Fisher A, Watling M, Smith A, Knight A. (2010). Pharmacokinetic comparisons of three nasal fentanyl formulations; pectin, chitosan and chitosan-poloxamer 188. Int J Clin Pharmacol Ther, 48:138-145.
7. Fisher A, Watling M, Smith A, Knight A. (2010). Pharmacokinetics and relative bioavailability of fentanyl pectin nasal spray 100 - 800 μg in healthy volunteers. Int J Clin Pharmacol Ther, 48:860-867.
8. Meltzer EO, Stahlman JE, Leflein J, Meltzer S, Lim J, Dalal AA et al. (2008). Preferences of adult patients with allergic rhinitis for the sensory attributes of fluticasone furoate versus fluticasone propionate nasal sprays: A randomized, multicenter, double-blind, single-dose, crossover study. Clin Ther, 30:271-279.
9. Mahadevia P, Shah S, Mannix S, Brewster-Jordan J, Kleinman L, Liebman C et al. (2006). Willingness to pay for sensory attributes of intranasal corticosteroids among patients with allergic rhinitis. J Manag Care Pharm, 12:143-151.
10. Portenoy RK, Raffaeli W, Torres LM, Sitte T, Deka AC, Herrera IG et al.; Fentanyl Nasal Spray Study 045 Investigators Group. (2010). Long-term safety, tolerability, and consistency of effect of fentanyl pectin nasal spray for breakthrough cancer pain in opioid-tolerant patients. J Opioid Manag, 6:319-328.
11. Taylor D, Galan V, Weinstein SM, Reyes E, Pupo-Araya AR, Rauck R; Fentanyl Pectin Nasal Spray 043 Study Group. (2010). Fentanyl pectin nasal spray in breakthrough cancer pain. J Support Oncol, 8:184-190.
12. Portenoy RK, Burton AW, Gabrail N, Taylor D; Fentanyl Pectin Nasal Spray 043 Study Group. (2010). A multicenter, placebocontrolled, double-blind, multiple-crossover study of Fentanyl Pectin Nasal Spray (FPNS) in the treatment of breakthrough cancer pain. Pain, 151:617-624.
13. Davies A, Sitte T, Elsner F, Reale C, Espinosa J, Brooks D et al. (2011). Consistency of efficacy, patient acceptability, and nasal tolerability of fentanyl pectin nasal spray compared with immediate-release morphine sulfate in breakthrough cancer pain. J Pain Symptom Manage, 41:358-366.
14. Harikarnpakdee S, Lipipun V, Sutanthavibul N, Ritthidej GC. (2006). Spray-dried mucoadhesive microspheres: Preparation and transport through nasal cell monolayer. AAPS PharmSciTech, 7:E12.
15. Kieweg SL, Geonnotti AR, Katz DF. (2004). Gravity-induced coating flows of vaginal gel formulations: In vitro experimental analysis. J Pharm Sci, 93:2941-2952.
16. Kockisch S, Rees GD, Young SA, Tsibouklis J, Smart JD. (2003). Polymeric microspheres for drug delivery to the oral cavity: An in vitro evaluation of mucoadhesive potential. J Pharm Sci, 92:1614-1623.
17. Eichner H, Behbehani AA, Hochstrasser K. (1983). [Diagnostic value of nasal secretions, current state: Normal values. 1]. Laryngol Rhinol Otol (Stuttg), 62:561-565.
18. Mahajan HS, Gattani SG. (2009). Gellan gum based microparticles of metoclopromide hydrochloride for intranasal delivery: Development and evaluation. Chem Pharm Bull, 57:388-392.
19. Kundoor V, Dalby RN. (2010). Assessment of nasal spray deposition pattern in a silicone human nose model using a color-based method. Pharm Res, 27:30-36.
20. Kundoor V, Dalby RN. (2011). Effect of formulation- and administration-related variables on deposition pattern of nasal spray pumps evaluated using a nasal cast. Pharm Res, 28:1895-1904.
21. Grape S, Schug SA, Lauer S, Schug BS. (2010). Formulations of fentanyl for the management of pain. Drugs, 70:57-72.
22. Fine PG. (1999). Clinical experience with Actiq® (oral transmucosal fentanyl citrate) for the treatment of cancer pain. Today's Therapeutic Trends, 17:1-11.
23. Mystakidou K, Tsilika E, Tsiatas M, Vlahos L. (2007). Oral transmucosal fentanyl citrate in cancer pain management: A practical application of nanotechnology. Int J Nanomedicine, 2:49-54.
24. Dumortier G, Grossiord JL, Agnely F, Chaumeil JC. (2006). A review of poloxamer 407 pharmaceutical and pharmacological characteristics. Pharm Res, 23:2709-2728.
25. Perez AP, Mundiña-Weilenmann C, Romero EL, Morilla MJ. (2012). Increased brain radioactivity by intranasal P-labeled siRNA dendriplexes within in situ-forming mucoadhesive gels. Int J Nanomedicine, 7:1373-1385.
26. Basu S, Bandyopadhyay AK. (2010). Development and characterization of mucoadhesive in situ nasal gel of midazolam prepared with Ficus carica mucilage. AAPS PharmSciTech, 11:1223-1231.
27. Majithiya RJ, Ghosh PK, Umrethia ML, Murthy RS. (2006). Thermoreversible-mucoadhesive gel for nasal delivery of sumatriptan. AAPS PharmSciTech, 7:67.
28. Cao SL, Zhang QZ, Jiang XG. (2007). Preparation of ion-activated in situ gel systems of scopolamine hydrobromide and evaluation of its antimotion sickness efficacy. Acta Pharmacol Sin, 28:584-590.
29. Cao SL, Ren XW, Zhang QZ, Chen E, Xu F, Chen J et al. (2009). In situ gel based on gellan gum as new carrier for nasal administration of mometasone furoate. Int J Pharm, 365:109-115.
30. Cai Z, Song X, Sun F, Yang Z, Hou S, Liu Z. (2011). Formulation and evaluation of in situ gelling systems for intranasal administration of gastrodin. AAPS PharmSciTech, 12:1102-1109.
31. Harish NM, Prabhu P, Charyulu RN, Gulzar MA, Subrahmanyam EV. (2009). Formulation and Evaluation of in situ Gels Containing Clotrimazole for Oral Candidiasis. Indian J Pharm Sci, 71:421-427.
32. Narayana RC, Harish NM, Gulzar A M, Prabhakara P, Singh AK, Subrahmanyam EV. (2009). Formulation and in vitro evaluation of in situ gels containing secnidazole for vaginitis. Yakugaku Zasshi, 129:569-574.
33. Gurny R, Boye T, Ibrahim H. (1985). Ocular therapy with nanoparticulate systems for controlled drug delivery. J Contr Release, 2:353-361.
34. Guo Y, Laube B, Dalby R. (2005). The effect of formulation variables and breathing patterns on the site of nasal deposition in an anatomically correct model. Pharm Res, 22:1871-1878.